News - Xin Weisheng

13 Nov 2024

From mundane to marvelous: The current and future uses of AI

Leveraging that experience, he moved to CAI, where he worked for five years running asset management reliability.
Find out more
22 Oct 2024

Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs

Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities
Find out more
20 Sep 2024

Just – Evotec Biologics Opens Its First J.POD Facility in Europe

Just– Evotec Biologics, the biologics segment of Evotec, celebrated the grand opening of its J.POD® biologics development and manufacturing facility located on Evotec’s Campus Curie in Toulouse, France.
Find out more
12 Aug 2024

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 million.
Find out more
12 Jul 2024

With Indian pharma under the scanner, 60 firms register under Centre’s scheme to upgrade their manufacturing facilities

New Delhi: Sixty small drug makers have joined a government scheme that promises financial incentives for modernizing their units in keeping with Indian attempts to sync with global good manufacturing practices.
Find out more
21 Jun 2024

Biovac, EuBiologics partner to boost Africa meningitis vaccine

South African biopharmaceutical manufacturer, Biovac, has signed a technology transfer agreement with global South Korean based manufacturer EuBiologics, for the technology transfer of a Meningococcal Meningitis pentavalent conjugate vaccine.
Find out more
27 May 2024

Tackling Manufacturing Failures for Viral Vectors

A company founded last year is hoping to tackle a major problem in gene therapy—the failure of therapies to reach the marketplace due to production failures.
Find out more
10 Apr 2024

Generic lomustine to be first product of US-based partnership

Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to produce lomustine, which is used to treat brain tumors.
Find out more
20 Mar 2024

Novo Invests $556M in China Operations to Boost Manufacturing Capacity

Novo Nordisk is investing approximately $556 million, or ¥4 billion, in a sterile preparations expansion project in its facility in China’s Tianjin city, the Danish drugmaker announced Tuesday in a Chinese-language announcement.
Find out more